Highest Score

Ranked by analysis score
Ranks this page's recent reports by score.
Churchill Downs Incorporated
CHDN·Consumer Discretionary
A ★★★★Buy
Current$94.83
Target$112.50
Return+18.6%
Oct 31, 2026

Churchill Downs combines a premium Kentucky Derby franchise and profitable historical racing assets with attractive valuation and potential deleveraging, although significant debt and uncertain casino divestment economics remain key risks.

Score
77
Sprouts Farmers Market, Inc.
SFM·Consumer Staples
A ★★★★Buy
Current$49.70
Target$57.00
Return+14.7%
Oct 31, 2026

Sprouts offers a differentiated, cash-generative specialty-grocery franchise at a compressed valuation with meaningful store-expansion potential, but weak comparable-store sales and rising reinvestment requirements threaten earnings recovery.

Score
77
Banco Bradesco S.A.
BBD·Financials
A ★★★★Buy
Current$2.55
Target$3.30
Return+29.4%
Oct 31, 2026

Banco Bradesco offers discounted exposure to a recovering Brazilian banking and insurance franchise, although rising credit delinquency and post-capital-increase dilution threaten the durability of per-share earnings growth.

Score
77
Markel Group Inc.
MKL·Financials
A ★★★★Buy
Current$1,869.82
Target$2,145.00
Return+14.7%
Oct 31, 2026

Markel combines profitable specialty insurance, investment float, and diversified operating businesses to compound per-share value over time, although reserve uncertainty and investment volatility can disrupt earnings and book-value growth.

Score
77
Regeneron Pharmaceuticals, Inc.
REGN·Healthcare
A ★★★★Buy
Current$927.89
Target$975.00
Return+5.1%
Oct 31, 2026

Regeneron's profitable Dupixent franchise, strong balance sheet, and expanding drug pipeline support long-term earnings growth, although EYLEA erosion, clinical setbacks, and a richer post-rally valuation limit the margin of safety.

Score
77
GSK plc
GSK·Healthcare
A ★★★★Buy
Current$49.51
Target$58.65
Return+18.5%
Oct 31, 2026

GSK offers profitable specialty-medicine growth, strong cash generation, and an attractive earnings valuation, but approaching HIV patent expirations and acquisition-related leverage could limit future returns.

Score
77
Evercore Inc.
EVR·Financials
A ★★★★Buy
Current$290.50
Target$341.12
Return+17.4%
Oct 31, 2026

Evercore combines an established independent advisory franchise, high returns on equity, and expanding M&A opportunities with an attractive earnings valuation, although cyclical deal activity and substantial employee compensation remain critical risks.

Score
77
Masco Corporation
MAS·Industrials
A ★★★★Buy
Current$80.64
Target$85.85
Return+6.5%
Oct 31, 2026

Masco combines durable home-improvement brands, high capital returns, and strong cash conversion with a credible earnings recovery, although housing cyclicality and a recent share-price rally limit near-term upside.

Score
77
Universal Health Services, Inc.
UHS·Healthcare
A ★★★★Buy
Current$176.05
Target$208.17
Return+18.2%
Oct 31, 2026

Universal Health Services offers substantial cash generation and a historically discounted valuation supported by durable hospital demand, although Medicaid reimbursement pressure and weakening acute-care margins threaten earnings recovery.

Score
77
Extra Space Storage Inc.
EXR·Real Estate
A ★★★★Buy
Current$149.90
Target$156.60
Return+4.5%
Oct 30, 2026

Extra Space Storage combines national self-storage scale, resilient property cash flow, and attractive dividends with improving NOI, although leverage, local supply competition, and limited valuation upside constrain returns.

Score
77
Armstrong World Industries, Inc.
AWI·Industrials
A ★★★★Buy
Current$165.95
Target$180.00
Return+8.5%
Oct 30, 2026

Armstrong combines a durable, high-return commercial ceiling franchise with faster-growing architectural specialties and shareholder-friendly capital allocation, although construction cyclicality and inflation could constrain margins and cash conversion.

Score
77
IQVIA Holdings Inc.
IQV·Healthcare
A ★★★★Buy
Current$275.06
Target$299.25
Return+8.8%
Oct 30, 2026

IQVIA combines durable clinical research outsourcing demand, differentiated healthcare data assets, and improving earnings momentum, although substantial leverage and clinical backlog execution risks limit its margin of safety.

Score
77